Call for Papers
Period of submission
Tuesday, September 30th - Friday, November 28th, 2025 (JST)
*Notification of acceptance or rejection will be sent via email in March, 2026.
Type of Presentation
The author can choose a preferred type of presentation. Please be advised that the Program Committee will make the final decision on the type of presentations regardless of your preference.
- Oral Presentation
- Poster Presentation
- Either will be fine
Abstract submission guidelines
- Please register by clicking the "abstract submission" button at the bottom of the page. Once the submission is completed, a confirmation email will be automatically. If you do not receive the confirmation e-mail within 24 hours after submission, please contact the Congress Secretariat (jspn122@m.congre.co.jp).
- You can revise your abstract as many times as you like during the abstract registration period.
Submission Guideline
- Title: up to 100 characters in single byte
- Body of abstract: up to 300 words in single byte
- Co-authors: up to 30 persons
- Affiliations: up to 10 affiliations
Categories
Please choose the category for your paper.
*Up to 3 categories can be registered.
*You are required to choose at least 1 category.
| 01 | Schizophrenia and related disorders | 26 | Neurochemistry |
|---|---|---|---|
| 02 | Mood disorders | 27 | Neuropathology |
| 03 | Neurotic disorders and related disorders | 28 | Genetics and molecular genetics |
| 04 | Personality disorders | 29 | Epidemiology |
| 05 | Epilepsy | 30 | Community mental health services |
| 06 | Dementia | 31 | Emergency psychiatry |
| 07 | Eating disorders-Behavioural syndromes associated with physiological disturbances and physical factors | 32 | Complications of physical illness in patients with mental illness |
| 08 | Organic and symptomatic mental disorders | 33 | Palliative care |
| 09 | Substance abuse and dependence | 34 | Consultation-liaison psychiatry |
| 10 | Mental disorders in childhood and adolescence | 35 | Early intervention |
| 11 | Perinatal menal health | 36 | Psychiatric diagnosis |
| 12 | Sleep disorders | 37 | Symptomatology |
| 13 | Mental retardation | 38 | Pharmacotherapy |
| 14 | Mental disorders in old age | 39 | Psychotherapy |
| 15 | Treatment-refractory severe mental disorders | 40 | Psychosocial therapy/psychoeducation |
| 16 | Gender and mental health | 41 | ECT/TMS/neuromodulation |
| 17 | Forensic psychiatry | 42 | Laboratory tests/biomarkers |
| 18 | Occupational mental health | 43 | Neuroimaging |
| 19 | Social psychiatry | 44 | Animal model/basic research |
| 20 | Mental health and welfare | 45 | Suicide prevention |
| 21 | Medical education | 46 | Disaster psychiatry |
| 22 | Psychopathology | 47 | Emerging infectious diseases (such as COVID-19) |
| 23 | Neuropsychology | 48 | AI |
| 24 | Neurophysiology | 49 | Psychiatric ethics |
| 25 | Psychopharmacology | 50 | Others |
Personal Information Protection
Please read and agree to the "Handling of personal information" in the form.
Congress Secretariat:
Congrès Inc.
Nakanoshima Qross 4-3-51 Nakanoshima, Kita-ku, Osaka 〒530-0005, Japan
E-mail: jspn122@m.congre.co.jp